Sucrase

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucrase

Quick Facts: Sucralfate Overview

Property Description
Active ingredient Sucralfate
Form Tablets, Oral Suspension
Pharmacological class Mucosal Protective Agent, Antiulcer Agent
General purpose Provides a physical barrier for damaged digestive lining
Origin Synthetic Compound

What Type of Medicine is Sucrase?

Sucrase is a trade name for a medication whose active component is Sucralfate, which is classified as a Gastrointestinal agent, specifically functioning as a Mucosal protective agent and an Antiulcer agent. This pharmacological class is defined by its ability to protect the delicate lining, or mucosa, of the digestive tract. Sucralfate is a synthetic compound, manufactured as a basic aluminum salt of sulfated sucrose. The formulation of Sucralfate is clinically recognized for its unique mechanism of binding to the gastrointestinal mucosa.

This profile positions Sucralfate as a local-acting drug, meaning it concentrates its therapeutic effects directly at the site of injury rather than modifying systemic body chemistry, which distinguishes it from systemically absorbed acid-reducing drugs. The medicine is primarily available as a prescription-only medication (Rx) for adults, with the distinguishing feature of the oral suspension form often being preferred for targeted coating of the upper esophagus.


What is the General Purpose of a Cytoprotective Agent?

The primary purpose of Sucralfate as a Cytoprotective agent is to create a physical, site-protective barrier over damaged tissue within the digestive lining. Upon oral administration, the drug's active component reacts with stomach acid, rapidly transforming into a viscous polymer that preferentially adheres to the proteinaceous material of exposed ulcers.

This barrier function is crucial for isolating vulnerable tissue from corrosive agents, including stomach acid and digestive enzymes. Sucralfate's mechanism effectively separates the ulcer bed from luminal contents, thereby promoting tissue repair. This demonstrates that the medication's core benefit is its ability to accelerate the body's natural healing process by securing the injury site.

Regulatory References

  1. NIH StatPearls Monograph on Sucralfate

What side effects are possible with Sucrase?

Possible Side Effects and Safety Information

The safety profile of Sucrase (sacrosidase) is primarily defined by reported gastrointestinal adverse reactions and specific warnings detailed in regulatory documentation, such as the US Food and Drug Administration (FDA) prescribing information.


Adverse Reactions and Systemic Effects

Adverse reactions reported in clinical studies largely involve the digestive system and are not formally classified using standard frequency categories (e.g., Common, Uncommon). The primary System-Organ Classes (SOCs) affected include:

  • Gastrointestinal Disorders: Reported effects include abdominal pain, diarrhea, nausea, vomiting, and constipation.
  • Nervous System Disorders: Documented reactions include headache and nervousness.
  • Psychiatric Disorders: Difficulty sleeping (insomnia) has been reported.
  • General Disorders: Includes reports of dehydration.

Serious Adverse Reactions and Safety Constraints

The most serious safety concern documented is the risk of Severe Hypersensitivity Reactions. These acute allergic responses, which can include wheezing, rash, swelling of the face or throat, and difficulty breathing, necessitate caution and observation, particularly during the initial doses of the medication.

Sucrase is contraindicated in patients with a known hypersensitivity to yeast, yeast products, papain, or glycerin (glycerol).


Population-Specific Safety Considerations

Regulatory documents include specific considerations for certain patient groups:

  • Diabetic Patients: Since Sucrase breaks down sucrose into glucose and fructose, which are then absorbed, there is a potential for changes in blood glucose levels.
  • Pediatric Use: Safety and effectiveness are established for patients five months of age and older.
  • Pregnancy: The medication is generally administered only if clearly needed.

These safety domains structure the understanding of the medicine's risk profile around gastrointestinal experience, allergic potential, and metabolic considerations for at-risk populations.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose information for Sucrase (Sacrosidase), strictly based on data from government regulatory authorities such as the U.S. Food and Drug Administration (FDA) prescribing information.


Documented Overdose Profile

The regulatory documentation for Sucrase indicates that overdosage has not been reported in clinical studies or literature. Consequently, the official labeling does not list specific symptoms, clinical signs, or severe outcomes associated with a pure overdose of the medication. This absence of documented clinical details is a key constraint in the official safety profile.


Required Emergency Actions

While specific manifestations are not documented, all suspected instances of overdose must be treated as a medical emergency requiring professional attention. The official prescribing information mandates immediate action.

Action Required Official Regulatory Instruction
Seeking Urgent Help Contact your doctor or go to the emergency room right away.
Clinical Management Treatment for a suspected overdose is supportive.

This means that no specific antidote is required, and management is limited to providing supportive care to the patient. No special monitoring requirements or population-specific considerations (e.g., for children or the elderly) are detailed in the official overdose section.

Therapeutic Uses of Sucrase

Easing Gastrointestinal Discomfort: Uses and Benefits

Sucrase (sacrosidase) is an oral enzyme replacement applied in addressing the group of gastrointestinal symptoms that often appear after consuming sucrose (table sugar) and starch. The medication is commonly used to help manage the symptoms of congenital sucrase-isomaltase deficiency (CSID).

Sucrase is applied in addressing symptom clusters that may become intense or disruptive, such as watery diarrhea, abdominal pain, bloating, and excess gas. This approach provides additional symptomatic support during phases of increased distress, contributing to improved day-to-day comfort.

Quick Fact: Supports Management of Digestive Discomfort

Sucrase is considered relevant in clinical settings involving CSID where symptoms cluster into patterns that create noticeable physiological strain and functional interference. It provides supportive relief when symptoms become temporarily overwhelming, helping patients cope more steadily with these difficult episodes. The medication is considered relevant in contexts involving heightened systemic burden.

“It supports the patient during phases of increased distress or discomfort by easing symptoms that may become intense or disruptive.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Sucrase?

The eligibility for Sucrase (sacrosidase) use is determined by official regulatory criteria, focusing on the patient's condition and history.

Eligibility Criteria

Category Official Regulatory Status
Primary Indication Patients diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID).
Minimum Age Established for use in pediatric patients 5 months of age and older.
Conditional Use Patients with Diabetes Mellitus require caution and careful monitoring due to the enzyme's effect on carbohydrate absorption.
Pregnancy Permitted only if clearly needed; use is generally considered acceptable during breastfeeding.

Contraindications (Who Must Not Use)

Sucrase is contraindicated and must not be used by patients with a known history of hypersensitivity (allergy) to the active enzyme or its components. This includes allergies to yeast, yeast products, glycerin (glycerol), or trace amounts of papain used in the manufacturing process.

Use is not established in infants younger than 5 months of age or in those with secondary (acquired) disaccharidase deficiencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sucrase (sacrosidase) is defined by constraints related to the enzyme’s stability, rather than systemic pharmacokinetic or pharmacodynamic interactions with other medicinal products. As a non-systemically absorbed replacement enzyme, Sucrase is not expected to engage in common drug-drug interactions involving metabolic pathways, such as CYP enzymes, or drug transporters. Regulatory documents confirm that neither drug-drug nor drug-food systemic interactions are anticipated or have been officially reported.

The documented interaction profile focuses on conditions that may reduce the drug’s enzymatic activity. The primary documented interaction-related restriction pertains to temperature. Co-administration with warm or hot fluids, beverages, or foods must be avoided, as the exposure to heat causes thermal denaturation, resulting in a loss of the drug’s effectiveness.

A second documented constraint is based on acidity. Substances that are acidic or rapidly change the gastric pH can also lead to a reduction in enzyme activity. Therefore, co-administration with acidic substances, such as fruit juice, is specifically restricted and must be avoided according to the product's official labeling. These requirements establish mandatory procedural constraints on concurrent food and liquid intake, which are based on maintaining the enzyme’s functional stability within the digestive tract.

Mechanism of Action

The pharmacological action of Sucralfate is defined by its localized, pH-dependent transformation, resulting in a dual mechanism that exclusively impacts the injured digestive lining.


️ Formation of an Acid-Activated Physical Barrier

This domain covers the primary, mechanical action where gastric acid (pH < 4) converts the inactive molecule into a viscous polyanion gel . This gel strongly electrostatically adheres to the exposed proteins found at the base of ulcers, creating a durable, protective cytoprotective barrier. This physical shield isolates the damaged tissue from highly corrosive acid and proteolytic pepsin, thereby reducing the direct exposure of the tissue to luminal aggressors.


Enhancement of Endogenous Mucosal Defense

This secondary domain involves the drug's role in supporting the body’s intrinsic healing processes. Sucralfate locally stimulates the production of Prostaglandin E2 ( PGE2), which significantly increases the secretion of protective mucus and bicarbonate ( HCO3^-) at the site of damage. This activity contributes to the maintenance of a local microenvironment conducive to repair, promoting cellular restitution and re-epithelialization via protection of growth factors (like EGF) required for tissue regeneration.

Dosage and Administration Information

How Sucrase (Sacrosidase) is Used: Official Administration Guidelines

Sucrase (sacrosidase) is administered only via the oral route as a solution and is taken as a long-term replacement therapy. The medication's standard usage protocol links the dose to the patient's weight and the timing to food consumption.

Official Dosing and Schedule

Parameter Official Instruction
Route of Administration Oral solution only.
Standard Dosing Schedule 2 mL (17,000 I.U.) for patients weighing over 15 kg; 1 mL (8,500 I.U.) for patients weighing 15 kg or less. The total daily dose should not exceed 8 mL.
Timing in Relation to Meals Administered with each meal or snack containing sucrose or starch. Half the dose should be taken at the beginning of the meal, and the remaining half should be taken during the meal or snack.
Age-Group Rules Approved for use in patients 5 months of age and older.
Missed-Dose Rule If a dose is missed, patients should skip the missed dose and continue with their regular schedule. Double doses must not be taken.

Preparation and Procedural Constraints

Sucrase solution must be diluted immediately before consumption. Approved liquids for dilution include water, milk, or infant formula that is cold or at room temperature. The medication should not be mixed with warm or hot liquids, as heating may decrease the enzyme’s potency. It is also noted that the solution should not be mixed with fruit juice or acidic beverages due to the risk of reduced enzyme activity.

For continuous use, the multiple-dose bottle must be discarded four weeks after opening to maintain product stability and quality, regardless of the amount of solution remaining.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sucrase (Sacrosidase)

The research evidence for Sucrase (sacrosidase) is centered on its role as an enzyme replacement for individuals with a diagnosis of Congenital Sucrase-Isomaltase Deficiency (CSID). The scientific studies reviewed by regulators explored the relationship between replacing the missing sucrase enzyme activity and patient experience.


Evidence Supporting Use in Congenital Sucrase-Isomaltase Deficiency (CSID)

The research base informing the regulatory review of Sucrase was primarily built on short-term, randomized, controlled trials (RCTs), where patient experience was compared against a placebo (an inactive substance). These studies were applied in research contexts involving fluctuating or unstable gastrointestinal symptoms typical of CSID, such as watery diarrhea, abdominal pain, and bloating. The populations included both pediatric patients (children 5 months of age and older) and adults who had been diagnosed with sucrase deficiency.

Studies monitored several key factors, including patient-reported experiences of discomfort, and measurements related to stool frequency and consistency. Research describes patterns observed in studies that examined how these measured outcomes evolved during the study period. Some trials reported data indicating patterns related to the frequency of stools and the number of formed or hard stools in the observed populations, and findings help contextualize how patients reported their experience during the short study period.


Focus of Long-Term Studies and Extended Follow-up

While the initial regulatory review relied on short-term, controlled trials, subsequent evidence has been derived from longitudinal observational studies that monitored patients over extended periods. These research activities explored the experience of individuals using the product for several months and, in some cases, for up to four years.

These longer studies monitored how patient-reported outcomes related to daily-life functioning evolved over the defined observation intervals. This evidence provides insight into long-term patterns observed in daily functioning or activity level. It helps provide data that short-term, controlled research cannot fully capture.


Research in Specific Patient Groups

Research so far indicates that studies have examined the enzyme replacement across a broad range of ages within the affected population. However, scientific literature also notes that data for certain groups remain insufficient. Specifically, there is limited information on the relationship of age to the measured outcomes in geriatric patients (older adults). Additionally, because of the rare nature of the condition, results apply only to the specific populations studied, and findings describing group patterns, not personal outcomes.


What Remains Unclear or Under-Studied

One major limitation is that the core research involved small sample sizes ( N) due to the rarity of CSID. Results, therefore, should be contextualized as reflecting group patterns rather than individual predictions. Furthermore, Sucrase was studied for the replacement of the missing sucrase enzyme, but the condition itself (CSID) also involves reduced isomaltase activity. Studies monitored the effect related to sugar digestion, but there is limited information regarding the treatment's effect on starch digestion, meaning the full impact of the product on the isomaltase deficiency component remains uncertain. Finally, long-term effects are not fully established, and certainty remains low regarding outcomes after many years of use.

Key Studies & References Sucrase-Isomaltase Deficiency: Clinical Practice Guidelines and Treatment Overview

Frequently Asked Questions (FAQ)

Common questions about Sucrase (FAQ)


Q: Is Sucrase the same as Lactase or other 'ase' enzymes?

Sucrase (sacrosidase) is an enzyme replacement that is specifically designed to help break down sucrose, or table sugar. The sucrase enzyme works differently from lactase, which is an enzyme that helps break down lactose (milk sugar). Official product information notes that patients with the target condition generally have normal levels of lactase enzyme activity.


Q: Is Sucrase considered a natural or synthetic medication?

The active ingredient in this medication is the enzyme sacrosidase, which is a purified form of sucrase. This enzyme is derived from baker's yeast, specifically Saccharomyces cerevisiae, making it a naturally-derived ingredient.


Q: Is Sucrase available over-the-counter or is it strictly prescription-only?

Sucrase (sacrosidase) oral solution is classified as a prescription-only medication (Rx). It requires a prescription from a healthcare professional for a patient to obtain and use it.


Q: What is the difference between Sucrase and Sacrosidase?

Sacrosidase is the pharmaceutical name for the active enzyme ingredient contained in the Sucrase oral solution. The medication, often known by a brand name, uses sacrosidase as the substitute enzyme to help the body break down sugars.


Q: What are the active ingredients in prescription Sucrase products?

The primary active ingredient in the solution is the enzyme sacrosidase. The medication also contains other components, such as a high concentration of glycerin (glycerol), which is part of the vehicle used to formulate the solution.


Q: Are there different strengths of Sucrase available, and why?

The oral solution is formulated to a standard concentration of 8,500 International Units (I.U.) of sacrosidase per 1 mL. It is supplied in single-use containers (2 mL) and multiple-dose bottles. The volume taken is tied to the patient's body weight, as outlined in the official dosing guidelines.


Q: Does taking Sucrase affect blood sugar levels in people without diabetes?

The enzyme works by breaking down sucrose into its simpler components, glucose and fructose, which are then absorbed into the bloodstream. Because this process results in the absorption of glucose, official product information notes the potential for changes in blood glucose levels.


Q: How does Sucrase help people with digestive issues?

Sucrase acts as an enzyme replacement for a genetically determined deficiency in the small intestine. By breaking down undigested sucrose, it helps reduce the buildup of sugar in the intestines. This action reduces the osmotic effect that typically causes symptoms like loose stools, excessive gas, and bloating.


Q: Can I take Sucrase along with my regular vitamins or mineral supplements?

Regulatory documents note that the drug is not expected to engage in systemic pharmacokinetic interactions with other drugs. However, official regulatory information suggests discussing all other medicines, including over-the-counter products, vitamins, herbal remedies, and supplements, with a healthcare professional.


Q: Does Sucrase interact with common pain relievers like ibuprofen or acetaminophen?

Specific systemic interactions with common pain relievers are not listed in regulatory documents. Official regulatory information suggests discussing all prescription and nonprescription medicines you are taking with a healthcare professional.


Q: Are there any specific foods or drinks that should be avoided when taking Sucrase?

To maintain the enzyme's effectiveness, the solution should never be mixed with warm or hot liquids, as heat can destroy the enzyme. It must also not be mixed with fruit juice or other acidic beverages, which can lead to a reduction in its activity.


Q: Does alcohol consumption affect how Sucrase works in the body?

Systemic interactions are not anticipated with alcohol. However, since the enzyme's activity can be reduced by acidic substances, this may be a relevant consideration for certain acidic alcoholic beverages. This can be discussed with a healthcare professional, as needed.


Q: Does the form of Sucrase (liquid, tablet, capsule) affect how well it works?

The product is officially authorized and supplied only as an oral solution. Regulatory documentation for this medication does not address the use or effectiveness of other forms, such as tablets or capsules.


Q: Are there genetic reasons why some people need Sucrase supplements?

The primary indication for this treatment is the replacement of the missing sucrase enzyme activity in individuals diagnosed with a genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).


Q: If I stop taking Sucrase, will my symptoms return immediately?

Sucrase is approved as a replacement therapy for a chronic enzyme deficiency. Since its function is to provide the missing enzyme needed for digestion, discontinuance of the therapy may result in a return of symptoms related to undigested sucrose.


Q: Do other medications commonly prescribed for stomach issues interact with Sucrase?

While systemic interactions are not expected, the medication's activity can be locally affected by substances that are acidic or rapidly change the gastric pH. This may be relevant to certain stomach medications.


Q: Does my diet need to change significantly while I am taking Sucrase?

Patients are instructed to follow any special diet provided by their healthcare professional. Official patient information notes that it may still be necessary to limit the amount of starch consumed in the diet.


Q: Is Sucrase used to treat any conditions besides enzyme deficiency?

The medication is indicated and approved only for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

How should Sucrase be stored and disposed of?

Storage and Disposal of Sucrase

Properly storing sucrase (sacrosidase) is essential to maintain its effectiveness. Store the oral solution at 2°C to 8°C (36°F to 46°F) in a refrigerator. Do not freeze the medication, as this can destroy the enzyme activity. Keep the bottle tightly closed in its original container and out of the reach of children.

Storage Condition Recommendation
Temperature Refrigerate (2°C to 8°C)
Freezing Do not freeze

When disposing of unused or expired sucrase, do not flush it down the toilet or pour it into a drain unless instructed to do so by a healthcare professional or an authorized drug take-back program. The best way to dispose of the medication is through a drug take-back program. Consult your pharmacist or local waste disposal company for more information on safe disposal practices.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucrase found in:

A-Z Index: